Astera Labs (ALAB) is having a good Monday. The stock is up nearly 6% as traders pile in ahead of the company's upcoming addition to the Nasdaq-100 index. It's a classic case of index inclusion mechanics meeting a risk-on tape.

The Nasdaq announced on June 12 that Astera Labs would join the index alongside CoreWeave (CRWV), Nebius Group (NBIS), Rocket Lab (RKLB), and Teradyne (TER). The changes take effect before the market opens on June 22. That means any ETF or passive fund tracking the Nasdaq-100 — including the massive QQQ, which manages over $300 billion — has to own these stocks. That mechanical demand creates a wave of buying pressure that can lift shares even before the official rebalance.

And the broader market is helping. The Nasdaq (QQQ) is up 3.12% today, and the Technology Select Sector (XLK) is leading all sectors with a 3.76% gain. The S&P 500 is up 1.93% with positive breadth — the advance/decline ratio sits at 1.8, and seven sectors are in the green. So Astera Labs is getting a double boost: stock-specific catalyst plus a strong tech day.

Astera Labs Stock: Key Levels and Momentum

Astera Labs has been on an absolute tear over the past year, with a 12-month gain of 312.61%. The stock is currently trading at $388.70, just shy of its 52-week high of $390.98. It's sitting well above its moving averages: 26.7% above the 20-day simple moving average, 63% above the 50-day, and a whopping 115.9% above the 200-day.

But momentum might be cooling a bit. The MACD indicator is currently below its signal line, which suggests that while the stock is still strong, the upward pressure may be fading. It's a reminder that even high-flying stocks can take a breather.

Earnings Preview: What to Watch

The next big catalyst for Astera Labs is its earnings report, expected around August 4, 2026. Here's what analysts are looking for:

• EPS Estimate: 64 cents, up from 44 cents a year ago
• Revenue Estimate: $360.21 million, up from $191.93 million
• Valuation: The stock trades at a P/E of 248.1x — a premium valuation by any measure

Analysts are generally bullish. The stock carries a Buy rating with an average price target of $237.69. Recent moves include:

• Evercore ISI Group: Outperform, raised target to $297.00 (May 19)
• Barclays: Equal-Weight, raised target to $200.00 (May 7)
• JPMorgan: Overweight, raised target to $280.00 (May 6)

Astera Labs shares were up 5.87% at $388.70 at the time of publication. The stock is trading near its 52-week high, and with index inclusion locked in, the buying pressure could continue into the June 22 effective date. But with a lofty valuation and momentum showing signs of fatigue, investors will be watching the earnings report closely.